Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I6LH
|
|||
| Former ID |
DNC001473
|
|||
| Drug Name |
Triptolide
|
|||
| Synonyms |
triptolide; 38748-32-2; Triptolid; PG490; UNII-19ALD1S53J; NSC 163062; CHEMBL463763; CHEBI:9747; 19ALD1S53J; C20H24O6; PG-490; CPD000466307; Triptolide, Tripterygium wilfordii; (-)-Triptolide; PG 490; Trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-c)furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-; SMR000466307; NSC163062; Triptolide, 1; Triptolide(PG490)/; AC1Q6AXN; BSPBio_001595; KBioGR_000315; KBioSS_000315
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Phase 3 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H24O6
|
|||
| Canonical SMILES |
CC(C)C12C(O1)C3C4(O3)C5(CCC6=C(C5CC7C4(C2O)O7)COC6=O)C
|
|||
| InChI |
1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1
|
|||
| InChIKey |
DFBIRQPKNDILPW-CIVMWXNOSA-N
|
|||
| CAS Number |
CAS 38748-32-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
11395, 438041, 10234537, 11121660, 11122140, 11362729, 11365291, 11367853, 11370729, 11370730, 11373454, 11376015, 11405618, 12013260, 14779021, 14828264, 26719814, 26756783, 26756784, 26759658, 44436900, 46386571, 47365335, 47736626, 49681800, 50058638, 50111424, 50148737, 53789857, 56313788, 57338365, 85788263, 92308503, 92310011, 99300923, 99302443, 103068676, 103080993, 103485733, 103911627, 104098578, 104380207, 117586588, 119526503, 124658951, 126645420, 126662434, 131404642, 134954205, 135066429
|
|||
| ChEBI ID |
CHEBI:9747
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02115659) Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). U.S. National Institutes of Health. | |||
| REF 2 | Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 2001 Nov 29;20(55):8009-18. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.